Karyopharm Therapeutics (KPTI)
Commercializer of the XPO1 inhibitor selinexor for blood cancers.
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis.
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis – – Total Revenue was $33.4 Million, and U.S. XPOVIO® (selinexor) Net Product Revenue was $30.8 Million for the Second Quarter of 2026 – – Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit – – If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of Therapy – NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis.
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow Patients for Longer-Term Outcomes – – The Safety and Tolerability Profile was Consistent with the Known Profile of Selinexor; No New Safety Signals Were Observed – – Company Prioritizing its Resources on its Myelofibrosis and Multiple Myeloma Programs; Company to Reduce Planned Investment in Endometrial Cancer – NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m.
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected by EHA's Scientific Program Committee as One of the Top Abstracts to be Presented – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral presentation at the 2026 European Hematology Association (EHA) Congress, taking place June 11 to 14 in Stockholm, Sweden.
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecified Subgroups – – Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline; Reductions in Symptoms Were Consistent Across Each Domain – – Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib, with Early Separation of the Kaplan-Meier Curves – – Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, will present the results of its Phase 3 SENTRY trial in a late-breaking oral presentation titled: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial (LBA6500) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting today.
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass.